| 7.73 0.08 (1.05%) | 11-19 15:31 | |||||||||||||
|
|
| Short term | ||||
| Mid term | |
|||
| Targets | 6-month : | 13.67 | 1-year : | 16.71 |
| Resists | First : | 11.7 | Second : | 14.31 |
| Pivot price | 8.59 |
|||
| Supports | First : | 7.5 | Second : | 6.24 |
| MAs | MA(5) : | 7.75 |
MA(20) : | 8.91 |
| MA(100) : | 11.74 |
MA(250) : | 10.77 |
|
| MACD | MACD : | -1.1 |
Signal : | -1 |
| %K %D | K(14,3) : | 11.1 |
D(3) : | 8.7 |
| RSI | RSI(14): 33.8 |
|||
| 52-week | High : | 14.68 | Low : | 7.23 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ORIC ] has closed above bottom band by 17.4%. Bollinger Bands are 15.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.06 - 8.11 | 8.11 - 8.14 |
| Low: | 7.42 - 7.48 | 7.48 - 7.53 |
| Close: | 7.56 - 7.65 | 7.65 - 7.72 |
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
Thu, 19 Nov 2026
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Target Lowered at HC Wainwright - MarketBeat
Tue, 17 Nov 2026
ORIC Pharmaceuticals, Inc. reports results for the quarter ended September 30 - Earnings Summary - TradingView
Tue, 17 Nov 2026
Oric Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $22.31, Implies 197% Upside - TradingView
Tue, 17 Nov 2026
ORIC Pharmaceuticals, Inc. (ORIC) stock price, news, quote and history - Yahoo Finance UK
Tue, 17 Nov 2026
ORIC Pharmaceuticals, Inc. (ORIC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Mon, 16 Nov 2026
ORIC Pharmaceuticals, Inc. (ORIC) stock price, news, quote and history - Yahoo Finance Australia
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 104 (M) |
| Shares Float | 89 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 123 (%) |
| Shares Short | 15,420 (K) |
| Shares Short P.Month | 17,530 (K) |
| EPS | -1.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.68 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26 % |
| Return on Equity (ttm) | -39.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -112 (M) |
| Levered Free Cash Flow | -69 (M) |
| PE Ratio | -5.86 |
| PEG Ratio | 0 |
| Price to Book value | 2.1 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |